Sulfasalazine and mesalamine modulate beryllium-specific lymphocyte proliferation and inflammatory cytokine production

American Journal of Respiratory Cell and Molecular Biology

Volumn 43, Issue 4, 2010, Pages 458-464

  Dobis, Dave R ^a   Sawyer, Richard T ^a,b   Gillespie, May M ^a   Newman, Lee S ^b,c   Maier, Lisa A ^a,b,c   Day, Brian J ^a,b,d  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Food Science and Human Nutrition   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Berylliosis; Granulomatous inflammation; IFN ; Lymphocyte proliferation; TNF

Indexed keywords

BERYLLIUM; MESALAZINE; SALAZOSULFAPYRIDINE; AUTACOID; CYTOKINE; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BRONCHOSCOPY; CELL PROLIFERATION; CELL STIMULATION; CELL VIABILITY; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG INHIBITION; FEMALE; GRANULOMATOSIS; HUMAN; HUMAN CELL; LUNG LAVAGE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE; ANTIGEN PRESENTING CELL; BERYLLIOSIS; BIOSYNTHESIS; CELL SURVIVAL; CHRONIC DISEASE; CYTOLOGY; DEMOGRAPHY; DRUG EFFECT; IMMUNOLOGY; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; ANTIGEN-PRESENTING CELLS; BERYLLIOSIS; BERYLLIUM; BRONCHOALVEOLAR LAVAGE FLUID; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC DISEASE; CYTOKINES; DEMOGRAPHY; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; MESALAMINE; MIDDLE AGED; SULFASALAZINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77958117555     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2009-0150OC     Document Type: Article

References (29)

1. Henneberger PK, Goe SK, Miller WE, Doney B, Groce DW. Industries in the United States with airborne beryllium exposure and estimates of the number of current workers potentially exposed. J Occup Environ Hyg 2004;1:648-659. (Pubitemid 39387567)
2. Fontenot AP, Kotzin BL. Chronic beryllium disease: Immune-mediated destruction with implications for organ-specific autoimmunity. Tissue Antigens 2003;62:449-458.
3. Newman LS, Mroz MM, Balkissoon R, Maier LA. Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. Am J Respir Crit Care Med 2005;171:54-60.
4. Maier LA, Sawyer RT, Tinkle SS, Kittle LA, Barker EA, Balkissoon R, Rose C, Newman LS. IL-4 fails to regulate in vitro beryllium-induced cytokines in berylliosis. Eur Respir J 2001;17:403-415.
5. + T cells in blood determines proliferative response. J Clin Invest 2005;115:2886-2893.
6. Mroz MM, Kreiss K, Lezotte DC, Campbell PA, Newman LS. Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease. J Allergy Clin Immunol 1991;88:54-60.
7. Rossman MD, Kern JA, Elias JA, Cullen MR, Epstein PE, Preuss OP, Markham TN, Daniele RP. Proliferative response of bronchoalveolar lymphocytes to beryllium: a test for chronic beryllium disease. Ann Intern Med 1988;108:687-693.
8. + T cells is mediated by HLA-DP. Am J Respir Cell Mol Biol 2004;31:122-130.
9. Sawyer RT, Abraham JL, Daniloff E, Newman LS. Secondary ion mass spectroscopy demonstrates retention of beryllium in chronic beryllium disease granulomas. J Occup Environ Med 2005;47:1218-1226. (Pubitemid 41813029)
10. Rom WN, Markowitz S, editors. Environmental and occupational medicine. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2007.
11. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000;118(2 Suppl 1)S68-S82.
12. Joshi R, Kumar S, Unnikrishnan M, Mukherjee T. Free radical scavenging reactions of sulfasalazine, 5-aminosalicylic acid and sulfapyridine: mechanistic aspects and antioxidant activity. Free Radic Res 2005;39:1163-1172. (Pubitemid 41601418)
13. - cystine transporter: a new action for an old drug. Leukemia 2001;15:1633-1640.
14. Dobis DR, Sawyer RT, Gillespie MM, Huang J, Newman LS, Maier LA, Day BJ. Modulation of lymphocyte proliferation by antioxidants in chronic beryllium disease. Am J Respir Crit Care Med 2008;177:1002-1011.
15. Kreiss K, Mroz MM, Zhen B, Martyny JW, Newman LS. Epidemiology of beryllium sensitization and disease in nuclear workers. Am Rev Respir Dis 1993;148:985-991.
16. Newman LS, Kreiss K, King TE Jr, Seay S, Campbell PA. Pathologic and immunologic alterations in early stages of beryllium disease: reexamination of disease definition and natural history. Am Rev Respir Dis 1989;139:1479-1486. (Pubitemid 19155510)
17. Stevens C, Lipman M, Fabry S, Moscovitch-Lopatin M, Almawi W, Keresztes S, Peppercorn MA, Strom TB. 5-aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J Pharmacol Exp Ther 1995; 272:399-406.
18. Doering J, Begue B, Lentze MJ, Rieux-Laucat F, Goulet O, Schmitz J, Cerf-Bensussan N, Ruemmele FM. Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease. Gut 2004;53:1632-1638.
19. Tinkle SS, Kittle LA, Schumacher BA, Newman LS. Beryllium induces IL-2 and IFN-gamma in berylliosis. J Immunol 1997;158:518-526. (Pubitemid 127483896)
20. + T cells in patients with beryllium-induced disease. J Allergy Clin Immunol 2005;115:1036-1042.
21. Sawyer RT, Maier LA, Kittle LA, Newman LS. Chronic beryllium disease: a model interaction between innate and acquired immunity. Int Immunopharmacol 2002;2:249-261.
22. Sood A, Beckett WS, Cullen MR. Variable response to long-term corticosteroid therapy in chronic beryllium disease. Chest 2004;126:2000-2007.
23. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005;127:1064-1071.
24. van Hees PA, Bakker JH, van Tongeren JH. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut 1980;21:632-635.
25. Neumann VC, Taggart AJ, Le Gallez P, Astbury C, Hill J, Bird HA. A study to determine the active moiety of sulphasalazine in rheumatoid arthritis. J Rheumatol 1986;13:285-287.
26. Freeman HJ. Granuloma-positive Crohn's disease. Can J Gastroenterol 2007;21:583-587.
27. Nieto N, Torres MI, Fernandez MI, Giron MD, Rios A, Suarez MD, Gil A. Experimental ulcerative colitis impairs antioxidant defense system in rat intestine. Dig Dis Sci 2000;45:1820-1827.
28. Murata Y, Ishiguro Y, Itoh J, Munakata A, Yoshida Y. The role of proinflammatory and immunoregulatory cytokines in the pathogenesis of ulcerative colitis. J Gastroenterol 1995;30:56-60.
29. Wendland BE, Aghdassi E, Tam C, Carrrier J, Steinhart AH, Wolman SL, Baron D, Allard JP. Lipid peroxidation and plasma antioxidant micronutrients in Crohn disease. Am J Clin Nutr 2001;74:259-264.